Plasma Kisspeptin Levels in Pregnancies with Diabetes and Hypertensive Disease as a Potential Marker of Placental Dysfunction and Adverse Perinatal Outcome
Authors:
- Aleksandar ĆetkovićAĆAleksandar Ćetković
- Dragana MiljicDMDragana Miljic
- Aleksandar LjubićALAleksandar Ljubić
- Michael PattersonMPMichael Patterson
- Mohammad GhateiMGMohammad Ghatei
- Jelena StamenkovićJSJelena Stamenković
- Marina Nikolic-DjurovicMNMarina Nikolic-Djurovic
- Sandra PekicSPSandra Pekic
- Mirjana DoknicMDMirjana Doknic
- Andreja GlišićAGAndreja Glišić
- Stephen BloomSBStephen Bloom
- Vera PopovicVPVera Popovic
- 18 October 2011
- journal article
- Published by Taylor & Francis in Endocrine Research
- Vol. 37 (2) , 78-88
Abstract
The aim of this study was to prospectively evaluate plasma kisspeptin levels in 129 singleton pregnancies with diabetes [pregestational insulin-dependent diabetes mellitus (type 1) and gestational diabetes (GD)] and hypertensive disease [chronic hypertension (CH), gestational hypertension, and preeclampsia (PE)] as a potential marker of placental dysfunction and adverse perinatal outcome. Kisspeptin levels were evaluated in the first, second, and third trimesters in patients with type 1 diabetes (16 patients), H (22), and healthy control (25) and in the second and third trimesters in patients with GD (20), gestational hypertension (18), and PE (28). Maternal kisspeptin levels were correlated with pregnancy outcome, parameters of fetoplacental circulation, ultrasound-detected abnormalities of placental morphology, and placental weight at delivery. In pregnancies with type 1 diabetes and H, mean kisspeptin levels were significantly lower compared with the control group (p<0.001 in the first and second trimesters and p<0.05 in the third trimester). Decreased plasma kisspeptin levels in the second and third trimesters were found in patients with GD (p<0.001 in the second and third trimesters) and PE (p<0.001 in the second trimester and p<0.05 in the third trimester). In patients with PE and placental dysfunction, low kisspeptin levels in the third trimester were associated with adverse perinatal outcome. Our study demonstrates reduced kisspeptin levels in pregnancies with diabetes, H, PE, and placental dysfunction. In patients with PE and placental dysfunction, decreased kisspeptin levels were associated with adverse perinatal outcome. Larger studies are needed to investigate the role of kisspeptin as a potential marker of placental dysfunction and adverse perinatal outcome.Keywords
This publication has 28 references indexed in Scilit:
- Do pregnancies with pre‐eclampsia have smaller placentas? A population study of 317 688 pregnancies with and without growth restriction in the offspringBJOG: An International Journal of Obstetrics & Gynaecology, 2010
- The effects of kisspeptin‐54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancyBritish Journal of Clinical Pharmacology, 2010
- First‐trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restrictionPrenatal Diagnosis, 2010
- Placental Structure in Type 1 DiabetesDiabetes, 2009
- Potential markers of preeclampsia – a reviewReproductive Biology and Endocrinology, 2009
- Vascular dysfunction in the diabetic placenta: causes and consequencesJournal of Anatomy, 2009
- Pre-eclampsiaThe Lancet, 2005
- Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblastsJournal of Cell Science, 2004
- The Metastasis Suppressor Gene KiSS-1 Encodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54Journal of Biological Chemistry, 2001
- KiSS-1, a Novel Human Malignant Melanoma Metastasis-Suppressor GeneJNCI: Journal of the National Cancer Institute, 1996